Clinical Trial Update: Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating single doses of GSK962040 in gastroparesis completed; no efficacy data provided in update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroparesis

Drugs mentioned

• GSK962040

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastroparesis | Phase 2 | Status: COMPLETED